Overview

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The objective of current protocol is try improve the results of chemotherapy treatment in patients with ALL wich is not indicated the peripheral stem cell transplant in first remission, with an intensive consolidation follow by re-inductions.
Phase:
Phase 4
Details
Lead Sponsor:
PETHEMA Foundation
Treatments:
6-Mercaptopurine
Asparaginase
Cyclophosphamide
Cytarabine
Daunorubicin
Mercaptopurine
Methotrexate
Prednisone
Vincristine